Burshell AL, Möricke R, Correa-Rotter R, Chen P, Warner MR, Dalsky GP, Taylor KA, Krege JH (2010) Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced
osteoporosis treated with teriparatide or alendronate. Bone 46:935–939PubMedCrossRef 17. Hochberg MC, Silverman SL, Barr CE, Miller PD (2010) The utility of changes in serum levels of C-terminal telopeptide of type I LY333531 in vivo collagen in predicting PD-1/PD-L1 Inhibitor 3 price patient response to oral monthly ibandronate therapy. J Clin Densitom 13:181–189PubMedCrossRef 18. Blumsohn A, Marin F, Nickelsen T, Brixen K, Sigurdsson G, González de la Vera J, Boonen S, Liu-Léage S, Barker C, Eastell R; EUROFORS Study Group (2011) Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide. Osteoporos Int 22:1935–1946CrossRef 19. Eastell R, Vrijens B, Cahall DL, Ringe JD, Garnero P, Watts NB (2011) Bone turnover markers and bone mineral density response with risedronate therapy: relationship with fracture risk and patient adherence. J Bone Miner Res 26:1662–1669PubMedCrossRef 20. Eastell R, Christiansen C, Grauer
A, Kutilek APR-246 chemical structure S, Libanati C, McClung MR, Reid IR, Resch H, Siris E, Uebelhart D, Wang A, Weryha G, Cummings SR (2011) Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res 26:530–537PubMedCrossRef
21. Tsujimoto M, Chen P, Miyauchi A, Sowa H, Krege JH (2011) PINP as an aid for monitoring patients treated with teriparatide. Bone 48:793–803CrossRef 22. Faulkner KG, Cann CE, Hasegawa BH (1991) Effect of bone distribution on vertebral strength: assessment with patient-specific nonlinear finite element analysis. Radiology 179:669–674PubMed 23. Crawford RP, Cann CE, Keaveny TM (2003) Finite element models predict in vitro vertebral body compressive strength better than quantitative Isoconazole computed tomography. Bone 33:744–750PubMedCrossRef 24. Griffith JF, Genant HK (2011) New imaging modalities in bone. Curr Rheumatol Rep 13:241–250PubMedCrossRef 25. Dall’Ara E, Pahr D, Varga P, Kainberger F, Zysset P (2012) QCT-based finite element models predict human vertebral strength in vitro significantly better than simulated DEXA. Osteoporos Int 23:563–572PubMedCrossRef 26. Keaveny TM, Donley DW, Hoffmann PF, Mitlak BH, Glass EV, San Martin JA (2007) Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. J Bone Miner Res 22:149–157PubMedCrossRef 27. Graeff C, Chevalier Y, Charlebois M, Varga P, Pahr D, Nickelsen TN, Morlock MM, Glüer CC, Zysset PK (2009) Improvements in vertebral body strength under teriparatide treatment assessed in vivo by finite element analysis: results from the EUROFORS study. J Bone Miner Res 24:1672–1680PubMedCrossRef 28.